Antiviral Chemotherapy 4

1. Front Matter

   Pages i-xiii

   PDF

2. Management of Genital Herpes

   • Gregory J. Mertz

   Pages 1-10

3. Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy

   • Lawrence Corey, Anna Wald, L. Gray Davis

   Pages 11-16

4. Famciclovir: Efficacy in Zoster and Issues in the Assessment of Pain

   • Ronald J. Boon, David R. J. Griffin

   Pages 17-31

5. Valacyclovir HCl (Valtrex™): An Acyclovir Prodrug with Improved Pharmacokinetics and Better Efficacy for Treatment of Zoster

   • M. Lynn Smiley, Alison Murray, Paulo de Miranda

   Pages 33-39

6. Sorivudine: A Potent Inhibitor of Varicella Zoster Virus Replication

   • Richard J. Whitley

   Pages 41-44

7. Summary of Panel Discussion about Antiviral Therapy for Zoster

   • Richard Whitley, Ann M. Arvin, Stephen E. Straus, Richard B. Pollard, Gregory J. Mertz

   Pages 45-47

8. Antiviral Drug Resistance in Herpes Simplex Virus

   • Donald M. Coen

   Pages 49-57

9. Treatment of Acyclovir-Resistant Herpes Simplex and Varicella Zoster Virus Infections

   • Sharon Safrin

   Pages 59-66

10. Therapeutic Immunization for Recurrent Herpes Simplex Virus Infections

    • Robin McKenzie, Stephen E. Straus

    Pages 67-83

11. Current Management of Cytomegalovirus Retinitis in Aids Update on Ganciclovir and Foscarnet for CMV Infections

    • Mark A. Jacobson

    Pages 85-92

12. Oral Ganciclovir for Cytomegalovirus Infections

    • Stephen E. Follansbee, Mary Jean Stempien, William C. Buhles

    Pages 93-103

13. A Preclinical and Clinical Overview of the Nucleotide-Based Antiviral Agent Cidofovir (HPMPC)

    • Jacob P. Lalezari, Robert J. Stagg, Howard S. Jaffe, Michael J. M. Hitchcock, W. Lawrence Drew

    Pages 105-115

14. Prophylaxis and Treatment of CMV Infections in Transplantation

    • John A. Zaia

    Pages 117-134

15. Cytomegalovirus: Genetics of Drug Resistance

    • Karen K. Biron

    Pages 135-143

16. Immunotherapy of CMV Infections

    • David P. Paar, Richard B. Pollard

    Pages 145-151

17. Hantavirus Infections in the United States: Diagnosis and Treatment

    • Gregory Mertz, Louisa Chapman

    Pages 153-162

18. Management of Respiratory Syncytial Virus Infections

    • John Mills

    Pages 163-174

19. Update on Therapy of Influenza and Rhinovirus Infections

    • Eurico Arruda, Frederick G. Hayden

    Pages 175-187

20. Therapy for Chronic Hepatitis B Infection

    • Norah A. Terrault, Teresa L. Wright

    Pages 189-205

The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary results would suggest that several of these classes of drugs will be licensed as well. Despite this optimism, however, there is increasing evidence that antiviral-resistant strains of pathogenic viruses will be a significant problem, perhaps especially with therapy of HIV infection, and there remains a desperate need for improved drugs (with either improved efficacy or decreased toxicity, or both) for CMV and HIV infections. This book is the edited proceedings of the Fourth Triennial Conference on Antiviral Chemotherapy, held in San Francisco, in November 1994. The conference was sponsored by the University of California, San Francisco, and co-sponsored by the International Society for Antiviral Research (ISAR), the Macfarlane Burnet Centre for Medical Research in Melbourne, Australia, and the Australian National Centre for HIV Virology Research. The conference had been organized to present an overview of the field of antiviral chemotherapy.

• AIDS
• HIV
• chemotherapy
• clinical trial
• drugs
• genetics
• immunotherapy
• infection
• infections
• pharmacokinetics
• research
• resistance
• transplantation
• virology
• virus

• Macfarlane Burnet Centre for Medical Research, Fairfield, Australia

  John Mills

• University of California San Francisco, San Francisco, USA

  Paul A. Volberding

• University of Washington, Seattle, USA

  Lawrence Corey

Policies and ethics